India has launched a new 7-minute injectable immunotherapy for eligible lung cancer patients with high PD-L1 expression. The subcutaneous version of Roche's atezolizumab aims to improve convenience and enhance treatment compared to traditional IV infusions. Doctors say the therapy could improve survival outcomes and quality of life for many patients with advanced non-small cell lung cancer.